ClinicalTrials.gg
CompletedNCT03698695Updated Jan 22, 2020

A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers

A Phase 1 interventional study of THN 201 and Donepezil in Cognitive Impairment and Alzheimer Disease, sponsored by Theranexus. Completed at 7 sites in France. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by Theranexus · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing donepezil in Cognitive Dysfunction — 1 open to participants now, 1 under way, none of them phase 3. Donepezil · Cognitive Dysfunction.

Enrollment
7th of 24
152 · median 70
Started
2018
the only one that year
Phase 1
4 of 25
none open now
Registered
21st of 25
by date

Among the 25 studies testing donepezil in Cognitive Dysfunction, this one is the 7th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2018, is one of 4 in phase 1, and was the 21st registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,122 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

1 of the 25 studies testing donepezil in Cognitive Dysfunction is open now. Recruiting first, the newest first:

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing donepezil in Cognitive Dysfunction, or all of them as a file.
02

Study summary

This study explores the safety, pharmacodynamics and pharmacokinetics of THN201 a combination of donepezil and mefloquine to improve cognitive function in healthy male volunteers after impairment by a scopolamine challenge.

Read the detailed description

This is a double-blind, 3-arm, parallel group study of 15 days duration including a scopolamine challenge at D15. Healthy male subjects will receive daily doses of THN201 (donepezil 5 mg and mefloquine), donepezil 5 mg or placebo and one subcutaneous injection of scopolamine 0.5 mg on D15. Cognitive function, EEG and P300 will be assessed at baseline and before and after scopolamine challenge at D15. A final safety evaluation will be performed 2 weeks after the end of the treatment period. Pharmacokinetic assessments will be performed to obtain a time/concentration profile of donepezil and mefloquine.

03

Conditions studied

  • Cognitive Impairment
  • Alzheimer Disease
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A (BMI), calculated as weight in kg/(height in m)², from 18 to 30 kg/m², inclusive
  • Healthy as determined by the investigator after a comprehensive clinical assessment based on medical history, physical examination, clinical laboratory test results, vital sign measurements, blood pressure (BP), heart rate (HR) and digital 12-lead readings (all results should be normal or, if out of range, they should be non- as determined by the investigator)

Exclusion criteria

Exclusion Criteria:

  • Any significant cardiovascular (e.g. heart failure), pulmonary (including asthma), hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidaemia), immunologic, dermatological, haematological, neurologic, psychiatric disease, history of any drug allergy, systemic or presence of infectious disease.
  • Current suicide risk or history of suicide risk (C-SSRS baseline: "yes" answer to items 4 and/or 5).
  • Brain imaging (MRI) at screening showing anatomical or vascular abnormality of any type.
  • EEG examination at screening showing abnormal (epileptiform) activities.
  • Symptomatic hypotension,
  • Participants with, or with a history of cardiac arrhythmia or cardiac disease or a personal or family history of long syndrome or a family history of sudden death.
  • Presence or history of drug , or allergic disease diagnosed and treated by a physician.
  • Antimalarial medicine intake or returning from a malaria-endemic area within the 12 last months before the first IMP administration.
  • Planning to visit a country requiring antimalarial chemoprophylaxis during the study period.
  • History of adverse reaction after a previous mefloquine intake.
  • for the use of Aricept® or for one of its .
  • Contraindication for the use of piperidine derivative compounds or for other cholinesterase inhibitors.
  • Contraindication for the use of Lariam® or for one of its excipients.
  • Contraindication for the use of scopolamine S.C. injection.
  • History or presence of drug or alcohol abuse (alcohol consumption > 21 units / week).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    THN201

    THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days

    Drug: THN 201

  • Active comparator
    Donepezil

    Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days

    Drug: Donepezil

  • Placebo comparator
    Placebo

    Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days

    Drug: Placebo

Interventions

  • THN 201: Donepezil 5 mg and Mefloquine 10 mg/d

    Also known as: Donepezil, Mefloquine

  • Donepezil 5 mg/d and Mefloquine placebo

  • DrugPlacebo

    Donepezil placebo and Mefloquine placebo

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics: Cognitive function measured with the Cognitive Drug Research (CDR) test battery

    Main variable: Power of attention is the sum of the speed scores (msec) from three tests: Simple Reaction Time, Choice Reaction Time, and Digital Vigilance. Low values indicate better performance

    Time frame: 15 days

Secondary outcomes

  1. Safety Adverse events

    Number of subjects with spontaneously reported treatment related adverse events

    Time frame: 29 days

Other outcomes

  1. Pharmacokinetics Plasma concentration of donepezil and mefloquine

    Time profile of plasma concentrations of donepezil and mefloquine

    Time frame: 29 days

  2. Pharmacodynamics measured by quantitative EEG (qEEG)

    Spectral analysis of absolute and/or relative amplitude in delta, theta, alpha, beta and gamma bands;

    Time frame: 15 days

  3. Pharmacodynamics measured by event related EEG potentials (P300)

    Auditory P300 parameters (amplitude, latency and AUC)

    Time frame: 15 days

07

Study locations

7 sites
  • CHU Bordeaux
    Bordeaux, France
  • CHU Clermont Ferrand
    Clermont-Ferrand, France
  • CHU Grenoble
    Grenoble, France
  • CHU Lille
    Lille, France
  • CHU Marseille
    Marseille, France
  • Biotrial
    Rennes, France
  • CHU Toulouse
    Toulouse, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2019, 12 months.

Of 26 industry-sponsored phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's 12 months is below that.

Counting every sponsor, half of 80 studies reached it within 27 months; a quarter within 13 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2018
First posted
Oct 9, 2018
StartActual
Sep 27, 2018
Primary completionActual
Oct 20, 2019
CompletionActual
Dec 20, 2019
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03698695
Lead sponsor
Theranexus
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Sep 27, 2018
Primary completion
Oct 20, 2019
Completion
Dec 20, 2019
Last update
Jan 22, 2020

Study contacts

Régis Bordet, Prof.
principal investigator · CHU Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion